Trial reportEuropean journal of nuclear medicine and molecular imaging2017
A PET/MRI study towards finding the optimal [
Trial report in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02076503 (Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Review
- Reprogramming natural proteins using unnatural amino acids.RSC advances · 2021Review
- Utility ofAJR. American journal of roentgenology · 2021Article
- The Role of [Cancers · 2021Article
- Value ofFrontiers in oncology · 2020Article
- Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer.Translational andrology and urology · 2018Review
- Article
- Comparison of time curves from dynamicPhysics and imaging in radiation oncology · 2018Article
- Update onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- SimultaneousFrontiers in oncology · 2018Article
- Fluorine-18 labeled amino acids for tumor PET/CT imaging.Oncotarget · 2017Review
- Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.Clinical and translational imaging · 2017Article
- Role of molecular imaging in the detection of localized prostate cancer.Therapeutic advances in urologyReview
- Target Volume Optimization for Localized Prostate Cancer.Practical radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[
methodsPatients diagnosed with high-risk primary prostate cancer underwent an integrated [
resultsTwenty-eight (28) patients [median (range) age: 66 (55-72) years] were included. An early (W1: 5-10 minutes post-injection) and two late candidate windows (W2: 18-23; W3: 33-38 minutes post-injection) were selected. Late compared with early imaging was better able to distinguish between malignant and benign tissue [W3, SUV
conclusionLate-window [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.